<DOC>
	<DOC>NCT00656461</DOC>
	<brief_summary>This is an open-label study to determine the highest dose of MKC-1 that may be administered daily on a continuous basis for patients with advanced or refractory solid tumors.</brief_summary>
	<brief_title>Phase 1 Study of MKC-1 in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective. Age greater than or equal to 18 years. ECOG performance status ≤1 ANC greater than or equal to 1,500/mm3; Platelets greater than or equal to 100,000/mm3 creatinine ≤1.5 times institutional upper limit of normal (ULN) T Bili within normal limits; AST and ALT less than or equal to 2.5 times ULN; and albumin greater than or equal to 3.0 g/dL have measurable disease by RECIST, radiographically evaluable disease, or detectable disease women of childbearing potential and men must agree to use adequate contraception Ability to understand and the willingness to sign a written informed consent document. Have previously received MKC1. Have received radiation to greater than 25% of the bone marrow. Have had anticancer therapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Are concurrently receiving any other investigational agents while on study. Have known brain metastases Have any condition that impairs the ability to swallow and retain MKC1 capsules. Uncontrolled intercurrent illness Are pregnant or breastfeeding HIVpositive patients Patients with uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Advanced cancer</keyword>
</DOC>